Novel compounds having inhibitory activity against sodium-dependant glucose transporter

Use of a compound of formula (IA): wherein R A is a halogen atom, a lower alkyl group or a lower alkoxy group; R B is a phenyl group optionally substituted by a halogen atom, a cyano group, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group, a halo-lower alkoxy group, or a mono- or di-lower alkylamino group; or a heterocyclyl group optionally substituted by a halogen atom, a cyano group, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group, a halo-lower alkoxy group, or a mono- or di-lower alkylamino group; and R c is hydrogen atom; or R B and R C taken together are a fused benzene ring which may be substituted by a halogen atom, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group or a halo-lower alkoxy group; in the manufacture of a medicament for the treatment of diabetes mellitus (type 1 and type 2), diabetic retinopathy, diabetic neuropathy, diabetic nephropathy, postprandial hyperglycemia, or delayed wound healing.